LadRx Issues 2024 Update to Shareholders

LOS ANGELES–(BUSINESS WIRE)–LadRx Corporation (OTCQB: LADX) (“LadRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today issued the below letter to shareholders providing a corporate update and anticipated milestones for 2024 regarding arimoclomol and LADR-7. *** January 9, 2024 Dear LadRx Shareholders, It…
Click here to view original post